Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine
Author:
- 1 December 2001
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 27 (6) , 351-363
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998
- Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanismsPharmacogenetics, 1996
- Hypoxanthine‐guanine phosphoribosyl‐transferase in childhood leukemia: Relation with immunophenotype, in vitro drug resistance and clinical prognosisInternational Journal of Cancer, 1992
- Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemiaThe Journal of Pediatrics, 1991
- Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood)British Journal of Haematology, 1991
- Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemiaThe Lancet, 1990
- The Purine Path to ChemotherapyScience, 1989
- Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemiaCancer Chemotherapy and Pharmacology, 1987
- Intensive consolidation chemotherapy for acute lymphoblastic leukaemia (UKALL X pilot study).Archives of Disease in Childhood, 1987
- Hypoxanthine-Guanine Phosphoribosyltransferase Activity in Normal and Leukaemic LymphocytesBritish Journal of Haematology, 1981